Health technology assessment: Second generation protocols;L'évaluation des technologies de santé: Les protocoles de deuxième génération

Journal d'Economie Medicale

Volumn 24, Issue 5, 2006, Pages 213-228

  Launois, R ^a   Payet, S ^a   Riou Franca L ^a   Le Lay, K ^a   Francesconi, C ^a   Devaux, M ^a   Quemener A ^a   Lootvoet, E ^a  

^a REES France   (France)

Author keywords

Acceptability curve; Bootstrap; Mix Treatment Comparisons; Monte Carlo analysis; Quantitative synthesis

Indexed keywords

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL TRIAL; HEALTH BEHAVIOR; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INFORMATION PROCESSING; MEDICAL DECISION MAKING; MEDICAL INFORMATION; META ANALYSIS; METHODOLOGY; OBSERVATIONAL STUDY; QUALITY OF LIFE; QUASI EXPERIMENTAL STUDY; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 33750332585     PISSN: 02940736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Riou França L, Launois R, Le Lay K, Aegezter P, Bouhassiza M, Meshaka P, Guidet B. Cost effectiveness of dotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. Inter J Tech Assess Health Care 2006;22(1):101-108.
2. Sonnenberg FA, Beck JR. Markov models in medical decision making. A practical guide. Medical Decision Making 1993;13:322-38.
3. Launois R, Croutsche JJ, Mégnigbêto A, Le Lay K, Portafax C. L'apport indispensable de l'épidémiologie clinique aux modèles de Markov. Journal d'Economie Médicale 1999;17(5):343-361.
4. Ades AE, Welton N, Lu G. Introduction to mixed treatment comparisons. MRC Health Services Research Collaboration.
5. Glenny AM, Altman DG, Song F, Sakarovitch C, Decks JJ, D'Amico R, Bradburn M, Eastwood AJ. Indirect comparisons of competing interventions. Health Technology Assessment 2005;9(26).
6. Ades AE, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. 2004. MRC Health Services Collaboration.
7. Thompson SG. Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. Statistical methods in medical research 1993;2:173-192.
8. Sutton AJ, Abrams KR, Jones DR. An illustrated guide to the methods of meta-analysis. Journal of Evaluation in Clinical Practice 2000;7(2):135-148.
9. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Statistical Methods in Medical Research 2001;10:277-303.
10. Thompson SG, Higgins J. How should meta-regression analyses be undertaken and interpreted? 2001. MRC Biostatistics Unit. Cambridge.
11. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technology Assessment 2000;4(38).
12. Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. 2002.
13. Parmigiani G. Measuring uncertainty in complex decision analysis models. Statistical Methods in Medical Research 2002;11:513-537.
14. Cooper NJ, Abrams KR, Sutton AJ, Turner D, Lambert PC. A Bayesian approach to Markov modeling in cost-effectiveness analyses: application to taxane use in advanced breast cancer. JR Statist Soc A 2003;166;part 3:389-405.
15. Cooper NJ, Sutton AJ, Abrams KR, Turner D et al. Comprehensive decision analytical modeling in economic evaluation: a bayesian approach. Health economics 2004;13:203-226.
16. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB. Recommandations of the panel on cost-effectiveness in health and medecine. JAMA 1996;276:1253-8.
17. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17: 479-500.
18. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985;5:157-77.
19. Claxton K, Scluper M, McCabe C et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optimal extra. Health Economics 2005;14:339-347.
20. Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P. The role of modelling in prioritising and planning clinical trials. Health Technology Assessment 2003;7(23).
21. Launois R. La recherche de l'efficience: un impératif déontologique. Médecine Sciences (NS) août 1990:25-30.
22. Launois R. Qu'est-ce que la régulation médicalisée. Journal d'économie médicale 1994;12:63-74.
23. Launois R, Lhoste F. Quelle place pour l'évaluation économique en matière de politique de santé? Journal d'Économie médicale 2002;20(2): 128-135.
24. Briggs AH, O'Brien BJ. The death of cost-minimisation analysis? Health Econ 2001;10:179-184.
25. Glick HA, Briggs AH, Polsky D. Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. Expert Rev Pharmacoeconomics Outcomes Res 2001;1(1).
26. O'Hagan A, Stevens JW, Montmartin J. Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio. Pharmacoeconomics 2000 Apr.;17(4):339-349.
27. Briggs AH. A bayesian approach to stochastic cost-effectiveness analysis. Health Economics 1999;8(3):257-261.
28. Heitjan DF, Moskowitz AJ, Whang W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Economics 1999;8:191-201.
29. Löthgren M, Zethraeus N. Definition, Interpretation and calculation of cost-effectiveness acceptability curves. Health Economics 2000;9:623-630.
30. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000 Jul-Sep;20(3):332-42.
31. World Health Organization. Making choices in health: WHO guide to cost effectiveness analysis. 2003. Edited by T Tan-Torres Edejer, R Baltussen, T Adam, R Hutubessy, A Acharya, DB Evans, CJL Murray.
32. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision making: How are cost-effectiveness thresholds expected to emerge? Value In Health 2004;7(5):518-528.
33. Launois R, Cartraud A, Perez V. Evaluation of integrated health delivery systems - example from France. In Preuß KJ, Räbiger J, Sommer JH (Eds): Managed Care - Evaluation und Performance-Measurement integrierter Versorfungsmodelle. Schattauer. Stuttgart 2001;Chap. 12:171-190.
34. Launois R, Mègnigbêto AC, Pérez V, Roy M, Camus A, Gailhardou M, Lançon F, Quéniart M. Expérimentation de la prise en charge de l'asthme en réseau de soins coordonnés® bilan de l'expérience RESALIS dans l'Eure, 18 mois avant et 12 mois après intervention. Journal d'Economie Médicale 2002;20(6):333-352.
35. Launois R. L'évaluation socio-économique une discipline entre recherche clinique et études observationnelles. Bull cancer 2003;90(1):97-104.
36. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
37. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, McNeil BJ. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001 Apr;54(4):387-98.
38. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998 Oct 15;17(19):2265-81.
39. Sznajder M, Aegerter P, Launois R, Merliere Y, Guidet B, CubRea. A cost-effectiveness analysis of stays in intensive care units. Intensive Care Med 2001 Jan;27(1):146-53.
40. Launois R. Un coût, des coûts, quels coûts? Journal d'Economie Médicale 1999;17(1):77-82.
41. Launois R, Vergnenègre A, Garrigues B. Notions et mesure des coûts en fonction de la perspective choisie. Bull Cancer 2003;90(11):946-54 repris dans Guide méthodologique pour l'évaluation des actions de santé, recommandations méthodologiques - CES Paris 2003. Annexe I.
42. Thomson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? British Medical Journal 2000;320:1197-1200.
43. O'Hagan A, Stevens JW. Assessing and Comparing Costs: How Robust are the bootstrap and the methods based on asymptotic normality? Health Economics 2003;12:33-49.
44. Zimmerman DW. Statistical Significance Levels of Nonparametric Tests Biased by Heterogenous Variances of Treatment Groups. Journal of General Psychology Oct 2000.
45. Zhou XH, Melfi CA, Hui SL. Methods for comparison of cost data. Ann Intern Med 1997;127(8 Part 2):752-756.
46. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001 Jul;20(4):461-94.
47. Desgagné A, Castilloux AM, Angers JF, LeLorier J. The Use of the Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed Data. Pharmacoeconomics 1998;13:487-497.